Document Detail

The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
MedLine Citation:
PMID:  23441979     Owner:  NLM     Status:  Publisher    
WHAT IS KNOWN AND OBJECTIVES: Pharmacists have the knowledge regarding optimal use of medications and the ability to influence physician prescribing. Successful interventions by a pharmacist to implement cardioprotective medications to a coronary artery disease patient's regimen would not only improve the patient's quality of care but may also increase his or her likelihood of survival. Therefore, the aim of this study was to (i) evaluate the effectiveness of pharmacist initiated interventions in increasing the prescription rates of acute coronary syndrome (ACS) secondary prevention pharmacotherapy at discharge, and to (ii) evaluate the acceptance rate of these interventions by prescribers. METHODS: This was a comparative study with a pre-intervention and post-intervention design. In the pre-intervention phase, a retrospective cross-sectional audit was performed. Patients with a diagnosis of acute coronary syndrome admitted to the hospital in the period from 2008 to January 2010 were identified from medical records and served as a historical control. The second phase (intervention phase) was conducted from the beginning of March to the end of September 2010. Two random samples of 190 patients with ACS were included. During the intervention phase, two hospital pharmacists made rounds with the cardiology team and gave secondary prevention recommendations when needed. The major reference for the recommendations was the Malaysian guidelines. RESULTS AND DISCUSSION: A total of 72 interventions were made by pharmacists of which drug initiation was most common (59.7%) followed by recommendations to change to another medication (23.6%) and optimization of medication dosing (16.6%). Most recommendations (72.2%) were accepted by prescribers. Majority of accepted recommendations were with β-blockers (38.46%) followed by those with angiotensin-converting-enzyme inhibitors (ACEI) (28.8%). The intervention had a significant impact on the utilization rates of β-blockers (increased from 75.8% to 84.7%, P = 0.028), angiotensin-converting-enzyme inhibitors/angiotensin II receptor bockers (from 65.3% to 74.7%, P = 0.044) and statins (from 91.6% to 98.4%, P = 0.002). The intervention had also led to a significant increase in the utilization rates of all these four classes together (from 42.6% to 62.6%, P = 0.001). WHAT IS NEW AND CONCLUSION: The study showed that the presence of a pharmacist on cardiology units increased the use of beta-blockers, aspirin, and statins for the secondary prophylaxis of ACS.
Y Hassan; Y Kassab; N Abd Aziz; H Akram; O Ismail
Related Documents :
23570539 - Medically unexplained symptoms and somatisation in ent.
24211029 - Increased risk among older veterans of prescribing psychotropic medication in the absen...
24606619 - Beyond prevalence to process: the role of self and identity in medical student well-being.
18629699 - Neurological caricatures since the 15th century.
23225289 - How do osteoporosis patients perceive their illness and treatment? implications for cli...
23669089 - Injury and illnesses prevention for ultramarathoners.
20836269 - Joyce after flaubert: the cuckold as imperfect physician, the writer as physiologist.
18694099 - Ambulatory electronic medical record payback analysis 7 years after implementation in a...
21351679 - Copayments for medications after june 30, 2010. final rule.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-26
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  -     ISSN:  1365-2710     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Department of Clinical Pharmacy, University Teknologi MARA, Selangor, Malaysia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in...
Next Document:  Toxic epidermal necrolysis.